---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Rehabilitative and communication therapies"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Rehabilitative and communication therapies. Topics: Consensus guideline: therapies to maintain and regain skills; Consensus guideline: augmentative and alternative communication and eye gaze devices; Communication guideline: international Delphi consensus; Systematic review: communication intervention studies, 2010 to 2022; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/rehabilitative-and-communication-therapies"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Rehabilitative and communication therapies

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Rehabilitative and Communication Therapies

<a id="topic-2.2.2.1.8-1"></a>

### Consensus guideline: therapies to maintain and regain skills

> “Skills can be maintained and possibly regained with vigorous therapies. Therapies to consider: speech therapy, feeding therapy, occupational therapy, augmentative communication therapy, vision therapy, hippotherapy (horse) and swim/pool therapy.”
> “Therapies for RTT should include occupational, physical, speech, swallowing and augmentative communication. Therapy that maximises physical activities should be lifelong, as these will minimise long-term complications and maximise long-term potentials.”
> “Consider occupational therapy (OT) and physical therapy (PT) consults for bracing and splinting. Consider neurology and physiatry consults for neuromuscular blockade or other medications to improve tone.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.8-2"></a>

### Consensus guideline: augmentative and alternative communication and eye gaze devices

> “Alternative and augmentative communication assessments are needed. While this can be done by some speech therapists, a specific referral may be needed. Since eye gaze is typically the most effective form of communication, special eye gaze devices can give individuals a voice. These referrals should be made as early as possible to coincide with typical language development.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.8-3"></a>

### Communication guideline: international Delphi consensus

> “All statements that reached a pre-determined threshold of ≥70% agreement were incorporated into guidelines that consist of 268 statements and recommendations relating to (a) rights of the individual; (b) beliefs and attitudes of communication partners; (c) professional knowledge and team work; (d) strategies to optimize engagement; (e) assessment; and (f) intervention (targets and goals, techniques), including the use of AAC.”
> “To date, this project is the largest of its kind, with 650 participants from 43 countries contributing to development of consensus-based guidelines for Rett syndrome.”

Source: [Townend et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32720526/)

<a id="topic-2.2.2.1.8-4"></a>

### Systematic review: communication intervention studies, 2010 to 2022

> “Across the 16 studies, intervention was provided to a total of 100 participants from 3 to 47 years of age. Half of the studies used systematic instruction to teach aided AAC.”
> “Positive outcomes (e.g., using AAC devices to make requests and/or initiate social-communication interactions) were reported in 13 of the studies.”

Source: [Sigafoos et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37526342/)

<a id="topic-2.2.2.1.8-5"></a>

### Eye gaze technology: family experiences in the Netherlands

> “20 respondents were using or had previous experience of using an eye gaze system at the time of the survey, 28 of those with no prior experience wanted to try a system in the future. Following a trial period, 11 systems had been funded through health insurance for long-term use and two families had decided a system was not appropriate for them.”
> “The majority of families reported progress in their child’s skills with longer term use.”

Source: [Townend et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4785214/)

<a id="topic-2.2.2.1.8-6"></a>

### Environmental enrichment: individually randomised stepped wedge trial

> “A genetically variable group of 12 girls with a MECP2 mutation and younger than 6 years participated in a modified individually randomised stepped wedge design study.”
> “The intervention comprised motor learning and exercise supplemented with social, cognitive and other sensory experiences over a six-month period.”
> “Adjusting for covariates, the enriched environment was associated with improved gross motor skills (coefficient 8.2, 95%CI 5.1, 11.2) and a 321.4 ng/ml (95%CI 272.0, 370.8) increase in blood BDNF levels after 6 months of treatment. Growth, sleep quality and mood were unaffected.”

Source: [Downs et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5764021/)

<a id="topic-2.2.2.1.8-7"></a>

### Systematic review: physical therapy approaches

> “Nine approaches to physical therapy for patients with Rett syndrome were identified: applied behavior analysis, conductive education, environmental enrichment, traditional physiotherapy with or without aids, hydrotherapy, treadmill, music therapy, computerized systems, and sensory-based treatment. It has been reported that patients had clinically benefited from the analysed approaches despite the fact that they did not have strong research evidence.”

Source: [Fonzo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7407501/)

<a id="topic-2.2.2.1.8-8"></a>

### Systematic review: utilization of physical, occupational, and speech therapy

> “Six studies examined ancillary service use, where PT utilization ranged from 24.4% to 100.0% and occupational therapy (OT) ranged from 11.5% to 91.7%. Pediatric patients demonstrated a two- to fourfold higher utilization of PT and OT services compared to adults.”
> “The two US-based retrospective claims analyses reported ST utilization rates of 74.1% and 13.3%, respectively [4, 11].”
> “For example, rehabilitation therapies such as PT, OT, and ST are commonly recommended as part of supportive management based on functional needs, but there is little RTT-specific evidence to define whether ongoing, episodic, intensive, or consultative therapy models are optimal at different ages [12, 37].”

Source: [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
